24 August 2022
The US Food and Drug Administration has finally given the long-awaited approval on Axsome Therapeutics’ depression drug. The approval has come after almost a year-long delay due to deficiencies in the company’s application that the FDA highlighted in August 2021. The drug, formerly called AXS-05, will be available for purchase in the last quarter of this year under the name Auvelity.
The lack of advanced, effective treatment options for depression (major depressive disorder) is well-known. This results in poor quality of life and leaves many struggling on a daily basis. Axsome Therapeutics’ Auvelity addresses the unmet need of hundreds of thousands of people suffering from MDD with its fast-acting mechanism, which is the primary factor that makes it stand out from the current roster of antidepressants on the market.
The response time for antidepressants that are currently available is six to eight weeks at minimum. But, according to what experts tell, Auvelity can show results within a week. Along with a quick improvement in symptoms, the patients can achieve remission by week two. As Lori Englebert, EVP Commercial and Business Development at Axsome, said, “The combination of these two is incredibly differentiating in the marketplace right now.” With the news of FDA approval becoming public, Axsome’s shares increased by over 36% within just a few hours.
Auvelity is an NDMA (N-methyl D – aspartate) receptor antagonist drug, the first of its kind in the antidepressant drugs sector. Spravato by Johnson & Johnson, which was previously (in 2020) endorsed as the first NDMA receptor antagonist drug for major depressive disorder, has a narrower mechanism of action than Axsome’s drug. Moreover, Spravato comes in the form of a nasal spray, whereas Auvelity is an oral medicine.
It’s the only NDMA receptor antagonist drug for MDD to be available as oral medicine. The broader label and pill form of Auvelity makes it a more viable option to be used as a first-line medication for MDD.
In clinical studies, Auvelity was found significantly superior to both placebo and bupropion sustained-release tablets in improving symptoms of MDD.
With its rapid-acting mechanism, the substantial magnitude of effects, ability to put people into remission quickly, and high tolerance, Auvelity offers hope to more than 17 million American adults who suffer from major depressive disorder. The hope for relief and living a better quality of life.
With finally getting the FDA’s approval after about a year-long extended review, Axsome is now preparing for the commercial release of the world’s first fast-acting antidepressant drug. But it’s not going to be an easy ride building the market for a brand new therapy. The company will have to invest a significant amount of time and money in building the marketing campaign and ensuring the availability of the drug.
Axsome Therapeutics hasn’t decided on the price for the drug yet but intends to start discussions on it with insurers in the coming few weeks, as it plans to begin rolling out the medicine for public use by the last quarter of this year.
Cara Delevingne is a supermodel who has recently surfaced showing signs of drug abuse and health concerns. Read on to learn more.
It is not like the younger generation doesn't drink at all; they do so in moderation because of the increased awareness of the side effects of alcohol, or maybe they have to drive home or avoid a hangover.
Read ahead to find out what greenwashing is and learn about 5 fast fashion brands that have been called out for greenwashing.
The micro-inverter market is made up of businesses that use the term "microinverter" to describe a small inverter that is fastened with every solar unit in a range to convert DC generated by solar panels to AC and sell light gauge steel framing.
Douglas Insights, one of the world's first comparison tools, has updated its database to reflect the market's prospects, advancements, driving factors, proje...
Douglas Insights has attempted to expand the growth of its comparison engine to include CCTV Cameras Market. The market reports include a massive trough of i...
Douglas Insights has analyzed various aspects of the battery recycling market (BRM) and revealed the changes in market trends due to consumer awareness relat...
Circulating tumour cell diagnosis and testing is becoming more common. It enables medical professionals to detect and quantify the tumour cells in the cancer...